Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 141 participants.

Also called NCT05450328

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 141 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05450328
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05450328. Randomized; triple masking; primary purpose treatment. Start 2025-12-10 (actual); primary completion 2028-05-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation
Acronym
MILAN
Condition
Right Heart Failure
Condition
Right Ventricular Dysfunction
Intervention (Drug)
Combined Epoprostenol Sodium & Milrinone
Intervention (Drug)
Normal saline
Lead sponsor
Montreal Heart Institute (class: other)

Record details

Record id
cardio:ct-nct05450328
Content hash
d47499d1fbb5cce307090b115ca2cef5729e3aa6af0e160e38f0efc9694bb5f2